2. Academic Validation
  3. Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p/HIGD1A axis

Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p/HIGD1A axis

  • J Adv Res. 2023 Jul 20;S2090-1232(23)00199-6. doi: 10.1016/j.jare.2023.07.007.
Jun-Lin Lv 1,  Yu-Jun Tan 2,  Yu-Shan Ren 3,  Ru Ma 1,  Xiao Wang 3,  Shu-Yan Wang 3,  Wan-Qing Liu 1,  Qiu-Sheng Zheng 1,  Jing-Chun Yao 4,  Jun Tian 5,  Jie Li 6
Affiliations

Affiliations

  • 1 School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, 264003 Yantai, China.
  • 2 School of Life Science, Jiangsu Normal University, 221116 Xuzhou, China.
  • 3 Department of Immunology, Medicine & Pharmacy Research Center, Binzhou Medical University, 264003 Yantai, China.
  • 4 State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., Ltd, 276000 Linyi, China. Electronic address: [email protected].
  • 5 School of Life Science, Jiangsu Normal University, 221116 Xuzhou, China. Electronic address: [email protected].
  • 6 School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, 264003 Yantai, China. Electronic address: [email protected].
PMID: 37479180 DOI: 10.1016/j.jare.2023.07.007
Abstract

Introduction: Although colon (COAD) and rectal adenocarcinoma (READ) combined to refer to colorectal Cancer (CRC), substantial clinical evidence urged that CRC should be treated as two different cancers due to compared with READ, COAD showed higher morbidity and worse 5-year survival.

Objectives: This study has tried to screen for the crucial gene that caused the worse prognosis and investigate its mechanism for mediating tumor growth and metastases in COAD. Meanwhile, the potential anti-COAD compound implicated in this mechanism was identified and testified from 1,855 food-borne chemical kits. This study aims to bring a new perspective to the development of new anti-COAD drugs and personalized medicine for patients with COAD.

Methods and results: The survival-related hub genes in COAD and READ were screened out from The Cancer Genome Atlas (TCGA) database and the results showed that HIGD1A, lower expressed in COAD than in READ, was associated with poor prognosis in COAD patients, but not in READ. Over-expressed HIGD1A suppressed CRC cell proliferation, invasion, and migration in vitro and in vivo. Meanwhile, the different expressed MicroRNA profiles between COAD and READ showed that miR-501-3p was highly expressed in COAD and inhibited HIGD1A expression by targeting 3'UTR of HIGD1A. MiR-501-3p mimics promoted cell proliferation and metastasis in CRC cells. In addition, Procyanidin C1 (PCC1), a kind of natural polyphenol has been verified as a potential miR-501-3p inhibitor. In vitro and in vivo, PCC1 promoted HIGD1A expression by suppressing miR-501-3p and resulted in inhibited tumor growth and metastasis.

Conclusion: The present study verified that miR-501-3p/HIGD1A axis mediated tumor growth and metastasis in COAD. PCC1, a flavonoid that riched in food exerts anti-COAD effects by inhibiting miR-501-3p and results in the latter losing the ability to suppress HIGD1A expression. Subsequently, unfettered HIGD1A inhibited tumor growth and metastasis in COAD.

Keywords

COADREAD; HIGD1A; Metastasis; Procyanidin C1; Tumor growth; miR-501-3p.

Figures
Products
Inhibitors & Agonists
Other Products